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We attempted to locate the glutamine residue in human vitronectin, susceptible to cross-linking by transglutaminases. Vitronectin was incubated 
with 14C-labelled putrescine and plasma factor XIIIa and, after reduction and alkylation, the vitronectin was digested with trypsin. HPLC of the 
digest followed by scintillation counting revealed one major and two minor radioactivity labelled peaks. Sub-digestion with Staphylococcus aureus 
protease, sequence analysis and mass-spectrometry of the resulting peptides demonstrated that Gln-93 of vitronectin had incorporated putrescine. 
Additionally, Gln-73, Gln-84 and Gln-86 were found to be minor sites for incorporation. 
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1. INTRODUCTION 
Vitronectin (VN) is a multifunctional glycoprotein 
present in human blood plasma at a concentration of - 
250 pg/ml [ 11. In its 75kDa single-chain form it is sen- 
sitive to proteolysis in the circulation. Therefore, part 
of the VN in plasma is in a two-chain form, consisting 
of a 65-kDa chain disulphide-bonded to a lo-kDa frag- 
ment [2]. VN has been purified in several aboratories 
[3-61. The complete amino-acid sequence (459 residues) 
deduced from the cDNA sequence [7,8] reveals that 
somatomedin B constitutes the 44 amino-terminal 
residues of VN [9]. These are followed immediately by 
an Arg-Gly-Asp sequence, which is part of the recogni- 
tion site for the VN receptor [lo]. The binding of VN to 
its receptor mediates the attachment and spreading of 
fibroblasts and epithelial cells [ 10,111, whence the name 
serum spreading factor is derived. VN inhibits the for- 
mation of the complement membrane attack complex 
through binding to the CSb-7 complex, thereby preven- 
ting the polymerization of C9 and its insertion into 
membranes [3,12]. In addition, VN binds to the [throm- 
bin:antithrombin III] complex and inhibits the 
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heparin-dependent formation thereof [ 13- 161. VN also 
binds plasminogen activator inhibitor 1 (PAI-1) in 
plasma [17,18]. 
Recently, it was shown that VN is a substrate for 
transglutaminases [ 191, and here we report the localiza- 
tion of the glutamine residue to which putrescine is 
cross-linked by FXIIIa-catalysed transamidation. 
2. MATERIALS AND METHODS 
VN was isolated from human plasma according to Dahlback and 
Podack [5] and frozen in the final buffer (0.01 M Tris, 0.15 M NaCl, 
pH 7.4; 395 pg/ml). FXIII was isolated from bovine plasma as 
described in reference [20] and purified further on Protein A- 
Sepharose (Pharmacia, Uppsala). Thrombin was a kind gift from Dr. 
J.W. Fenton II (State Department of Health, Albany, NY). 
In the labelling experiment, 3 mg VN was thawed and made 15 mM 
in CaClz. 3 mg putrescine (Sigma, St. Louis, MO) containing 25 pCi 
[1,4-%)]putrescine (109 mCi/mmol, Amersham) was added. 0.5 mg 
FXIII (1 mg/ml) was activated (1 h, 37’C) with 1Opg thrombin (4000 
U/mg) and added to the VN/putrescine solution. The reaction mix- 
ture (vol. 10.5 ml) was incubated for 4 h at 37°C. 
Reduction and carboxymethylation of VN was performed directly 
in the VN/FXIIIa/putrescine reaction mixture as follows: urea, Tris 
and EDTA were added so as to give a final concentration of 8 M urea, 
0.2 M Tris and 20 mM EDTA (final volume 20 ml, pH 8.2). 3 mg 
dithioerythritol (Merck, Darmstadt) was added and the mixture was 
incubated for 1 h at 20°C. A surplus of iodoacetic acid (Merck, 
Darmstadt) was then added and the mixture was incubated for l/2 h 
at 20°C. 
Desalting of the resulting solution was performed on a column of 
Sephadex G-25 (Pharmacia, Uppsala; 2 x 60 cm) in 0.1 M am- 
monium bicarbonate. The protein peak (20 ml) was digested by direct 
addition of 100/g trypsin (Worthington, Freehold, NJ) (22 h, 37°C). 
Soybean trypsin inhibitor (Sigma) was added and the solution was 
freeze-dried. 
00145793/90/$3.50 0 1990 Federation of European Biochemical Societies 269 
Volume 262, number 2 FEBS LETTERS March 1990 
A 
__ 
t- 
0 
225 
____. 
--f 
i 
I 1 1 1 , co 
5 10 15 20 25 30 35 
TIME (mid 
Fig.1. HPLC separation of peptides obtained from VN by digestion with trypsin. A Nucleosil Crs 7p column (0.4 x 24 cm) was used, eluted with 
a three-step linear gradient of 96% ethanol (B) in 0.1% triff uoroacetic acid (A). The flow rate was 1 ml/mitt. (-) Azsnm (arbitrary units); 
(- - -) %B. Peaks 16, 19 and 20 were radioactive. 
Separation of fragments and peptides was carried out by reverse- 
phase HPLC with a Hewlett Packard 1084B liquid chromatograph, 
and aliquots from each peak were counted in a scintillation counter 
(Beckman LS 1801). 
Peptide hydrolysates were analysed in a Hewlett Packard Amino 
Quant analyzer. Amino-acid-sequencing was performed by 
automated Edman degradation with an Applied Biosystems 477A or 
470A gas-phase amino-acid sequencer, and PTH derivatives were 
identified by reverse-phase HPLC by using an Applied Biosystems 
Model 12OA PTH amino acid analyzer or a Hewlett Packard 1084B 
liquid chromatograph. 
Mass-s~trome~y was performed by using a BioIon 1OK plasma 
desorption time-of-flight instrument. Samples were dissolved in 0.1% 
trifluoroacetic acid and applied to nitrocellulose-covered targets, 
spin-dried and micro-rinsed as described [21]. Spectra were recorded 
at 16 kV for lo6 primary fission events. 
Standard chemicals were from Merck, Sigma or Fluka (Buchs). S. 
aureus protease was from Worhtington. 
3. RESULTS AND DISCUSSION 
One major and two minor radioactively labelled 
peaks were found in the tryptic digest of the 14C- 
labelled VN (fig.1). The major peak (peak 20) was se- 
quenced and the N-terminal sequence was GNPE- 
QTPVLKPEEEA, corresponding to residues 89-103 of 
VN. Scintillation counting of the PTH amino acids 
showed radioactivity in cycle 5. To make certain that 
this was the only iabelled glutamine in the major 
radioactive peak, the fragment was sub-digested with S. 
aureus protease. The resulting peptides were separated 
by HPLC (fig.2) and aliquots were scintillation 
counted. Only one radioactive peak was found (peak 
14), and sequencing of this peptide gave the amino acid 
sequence QTPVLKPEEEAPAPE (VN 93-107). The 
yield of the glutamine in cycle one was very low (7 
pmol) compared with the yield in other cycles (169, 152 
270 
and 158 pmol in cycles 3 (Pro),4 (Val) and 5 (Leu), 
respectively) (table I), indicating that the putrescine 
moiety was linked to this Gln-1. Scintillation counting 
of the PTH amino acids confirmed this, showing 
radioactivity in cycle 1 (table 1). As a final confirma- 
tion, the peptide was analysed by mass spectrometry. 
This showed the mass of the intact molecule to fit the 
mass calculated for the peptide including putrescine 
(fig.3B). The same peptide, without an attached 
putrescine moiety, was identified in a neighbou~ng 
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Fig.2. HPLC-purification of peptides obtained from peak 20 (in 
fig.1) by digestion with S. uureus protease. A Nucleosil Cl8 7,~ column 
(0.4 x 24 cm) was used, eluted with a three-step linear gradient of 
80% acetonitrile, 0.02% trifhroroacetic acid (B) in 0.1% trifluoro- 
acetic acid (A). The ffow rate was 1 ml/mitt. (-) A2rsnm (ar- 
bitrary units); f- - -) %B. Peak 14 was radioactive. 
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Table 1 
Sequence of the [‘4C]putrescine labelled S. aureus protease peptide, VN (93-107), 240 
pmol, from peak 15 (fig.2) 
Cycle Position Known Found Pm01 Radioactivity 
sequence sequence CDrn 
1 93 Gln (Gln) 7 79 
2 94 Thr Thr 94 47 
3 95 Pro Pro 169 45 
4 96 Val Val 152 37 
5 97 Leu Leu 158 35 
6 98 Lys Lys 113 39 
7 99 Pro Pro 148 39 
8 100 Glu Glu 59 35 
9 101 Glu Glu 70 37 
10 102 Glu Glu 84 40 
11 103 Ala Ala 95 44 
12 104 Pro Pro 93 40 
13 105 Ala Ala 94 49 
14 106 Pro Pro 89 36 
15 107 Glu (Glu) 13 39 
345 
1 1636.0 
17063 
Fig.3. (A) PDMS spectrum of fraction 15 (fig.2), showing the MH+ ion (m/z 1636.0) of unmodified VN (93-107) peptide. A small amount of the 
same peptide with putrescine attached is present (MH+ ion of m/z 1707.6). The peaks at 838.6 and 851.8 arise from an unidentified impurity. (B) 
PDMS spectrum of fraction 14 (fig.2), showing the MH+ ion of the putrescine linked VN (93-107) peptide (m/z 1706.3). The peaks at m/z 1590.6 
(A) and m/z 1663.5 (B) arise from loss of CO2 and the m/z 1727.5 peak (A) is a sodium adduct ion. 
271 
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Fig.4. HPLC-purification of peptides obtained from peak 16 (in 
fig. 1) by digestion with S. aureus protease. The column and gradient 
used were the same as in fig.2. Peaks 5, 22 and 23 were radioactive. 
fraction, containing slightly more protein (peak 15, 
fig.2) (fig.3A). 
The two minor radioactively labelled peaks (peaks 16 
and 19, fig. 1) were analyzed in the same way as peak 20. 
The N-terminal sequence of peak 19 was the same as 
that of peak 20, except that an additional sequence, 
GQYXYELDEK, corresponding to residues 1% 167 of 
VN, was found. This could be explained by a disulfide 
bridge between Cys-137 and Cys-161, which was still in- 
tact, despite the reduction and alkylation. Digestion 
with S. 0ureu.s protease and separation of peptides by 
HPLC (not shown), under the same conditions as in 
fig.2, revealed a radioactive peptide identical to that 
found in peak 14, fig.2. In addition, the presence of a 
disulfide bridge between Cys-137 and Cys-161 was con- 
firmed by the isolation of the peptide 
137 
LCSGKPFDAFTDLK 
I 
GQYCYE 
161 
The N-terminal sequence of peak 16 showed a mix- 
ture of two sequences, DQESXKGRXTE (residues l-l 1 
of VN) and GDVFTMPEDE (residues 46-55 of VN), 
and none of the resulting PTH amino acids were 
radioactive. The fragment mixture was then digested 
with S. aureus protease and the resulting peptides were 
separated by HPLC (fig.4). Three radioactively labelled 
peaks were identified (peaks 5,22 and 23). Sequencing 
of these gave LQAQSK for peak 5 and QVGGPSLT- 
SDLQAQSK for peaks 22 and 23, corresponding to 
residues 83-88 and 73-88 of VN. These peptides are ob- 
viously cleavage variants, originating from an in- 
complete cleavage by S. aureus protease at Asp-82. The 
yields of Gln-73, Gln-84 and Gln-86 were relatively low 
and scintillation counting of the PTH amino acids gave 
weak indication of radioactivity in Gln-73 and Gln-86 
(table 2). Mass spectrometry of peptide VN 83-88 show- 
ed a molecular mass that indicated the presence of a 
single putrescine unit (fig.5). Mass spectrometry of the 
VN 73-88 peptide from peak 22 showed the presence of 
two peptides with masses corresponding to attachment 
of one and two putiescine units, respectively (fig.6B). 
The neighbouring peak in the HPLC chromatogram 
(peak 23) contained the identical peptide without 
putrescine, but also a small amount of the peptide with 
one unit attached (fig.6A). 
The results shown in this paper demonstrate clearly 
that VN is a substrate for FXIIIa and that putrescine 
Table 2 
Sequence of the [‘4C]putrescine labelled S. aureus protease peptides, VN (73-88), 100 pmol 
and VN (83-88), 170 pmol, from peaks 23 and 5 (fig.4) 
Cycle Position Known Found Pm01 Radioactivity 
sequence sequence cpm 
1 73 Gin 
2 74 Val 
3 75 GlY 
4 76 GUY 
5 77 Pro 
6 78 Ser 
7 79 Leu 
8 80 Thr 
9 81 Ser 
10 82 Asp 
11 83 Leu 
12 84 Gln 
13 85 Ala 
14 86 Gln 
15 87 Ser 
16 88 Lys 
Gln 29 48 
Val 64 36 
GlY 70 34 
Gly 73 37 
Pro 53 33 
Ser 45 33 
Leu 47 36 
Thr 36 29 
Ser 26 28 
Asp 13 36 
Leu 23 156 31 33 
Gln 6 68 38 34 
Ala 27 117 39 30 
Gln 9 48 35 46 
Ser _ 47 - 34 
Lys - 26 - 34 
272 
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Fig.5. PDMS spectrum of peak 5 (fig.4). The MH’ ion at m/z 745.8 corresponds to the VN 83-88 peptide with one putrescine unit attached. 
Fig.6. (A) PDMS spectrum of peak 23 (fig.4). The MH+ ion at m/z 1617.1 corresponds to the VN 73-88 peptide and the MH+ ion at m/z 1687.6 
is the same peptide with one putrescine unit attached. (B) PDMS spectrum of peak 22 (fig.4). This fraction contains the same peptide as spectrum 
A, but with one (m/z 1688.2) or two (m/z 1759.6) putrescine units attached. 
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Fig.?. Amino-acid sequence around the putative FXIIIa cross-linking 
site(s) in VN (*). The sequence is from [7,8]. The cleavage sites for 
trypsin (T) and S. aureus protease (Sp) are indicated. Gln-93 is the 
major cross-linking site, while Gln-73, Gln-84 and Gin-86 are minor 
sites. 
can be linked to Gln-93 of VN (fig.7). Additionally, at 
least two out of three other glutamine residues nearby 
(Gin-73, Gln-84 and Gin-86) are also susceptible to 
transamidation catalysed by FXIIIa. The cross-linking 
sites are located in a negatively charged connecting 
strand (residues 45-131) between the somatomedin B 
domain [22] and the first of two hemopexin domains 
[23]. The connecting strand in addition contains the 
RGD cell adhesion sequence, a potential N-glyco- 
sylation site [7,8] and two putative tyrosine sulfation 
sites [24]. 
As an additional finding, a disulfide bridge connec- 
ting Cys-137 to Cys-161, was identified. 
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